The United States of America, As Represented by the Secretary, Department of Health and Human Services

The United States of America As Represented by the Department of Health

University of Denver

National Institutes of Health, Office of Technology Transfer

University of Georgia Research Foundation, Inc.

Stuart T Nichol

Thomas G Ksiazek

Pierre E Rollin

Brian H Bird

Cesar G Albarino

Jonathan S Towner

Christina F Spiropoulou

James A Comer

Scott Dusan Pegan

Sergey Morzunov

Eric Bergeron

Michelle Kay Deaton

Cynthia Goldsmith

César Albariño

Eugeny Ravkov

Luanne Elliott

William L Nicholson

Aubree Kelly

Laura K McMullan

Kimberly A Dodd

Ute Stroeher

Tara Sealy

Jessica R Spengler

Laura K Mcmullan

Stephen R Welch

Florine E M Scholte

Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.

Human ebola virus species and compositions and methods thereof

Probes and primers are disclosed for detecting EBOV nucleic acid in a sample. Methods are also disclosed that utilize these probes and primers, wherein the methods can be used to detect an EBOV in a sample to identify a subject with an EBOV infection.

Methods and reagents for detecting ebola virus

Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.

Recombinant rift valley fever (RVF) viruses and methods of use

The genetically modified nairoviruses of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Exemplary are Crimean-Congo hemorrhagic fever virus and Erve virus. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent for prophylaxis and treatment.

Attenuated live vaccine for Crimean-Congo hemorrhagic fever virus and Erve virus

Human Ebola virus species and compositions and methods thereof

Disclosed herein is a robust system for the reverse genetics generation of a Rift Valley fever (RVF) virus replicon particle (VRP) vaccine candidate. VRPcan actively synthesize viral RNA and proteins, but lack structural glycoprotein genes, preventing spread within immunized individuals and reducing the risk of vaccine-induced pathogenicity. Is it disclosed herein that VRPimmunization is both safe and efficacious, resulting in a robust immune response that is protective against RVF virus challenge within 24 hours of immunization. Provided herein are VRP, methods of producing VRP, and method of using VRPfor immunization against RVF virus infection.

Rift valley fever virus replicon particles and use thereof

The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent.

Crimean-Congo hemorrhagic fever virus vaccine

Recombinant rift valley fever (RVF) viruses and methods

Described herein are the clinical and laboratory characteristics of two patients bitten by ticks and infected with a unique member of the genus(family Bunyaviridae) with a proposed name of Heartland virus (HRTLV). Provided herein are nucleotide and amino acid sequences of theisolates, primers and probes that specifically hybridize with theisolates, and antibodies specific for theproteins. Also provided are detection assays using thenucleic acid molecules, proteins, probes, primers and antibodies. Further provided are recombinantand their use for eliciting an immune response in a subject.

Pathogenic phlebovirus isolates and compositions and methods of use

Recombinant Rift Valley fever (RVF) viruses and methods of use

The present invention relates to the discovery of a novel Hantavirus. In particular, the present invention relates to nucleic acids of the newly discovered virus and to nucleic acid reagents and antibodies for use in methods of detection and prevention of infection by the virus.

Polypeptides of a novel hantavirus

Strain of hantavirus nucleotide sequences thereof related probes,

The present invention relates to the discovery and isolation of a novel hantavirus designated the Bayou hantavirus. In particular, the present invention relates to nucleic acids of the newly discovered virus and to nucleic acid reagents (primers and probes), purified polypeptides and antibodies for use in methods of detection and prevention of infection by the virus. A vaccine or purified immunogenic polypeptide of the Bayou hantavirus in a pharmaceutically acceptable carrier is provided. A vector comprising the nucleic acids of the invention is provided. A method of detecting the presence of a hantavirus in a subject comprising contacting an antibody-containing sample from the subject with a purified polypeptide of the invention and detecting the reaction of the polypeptide and the antibody is provided. A method of detecting the presence of the Bayou hantavirus is provided comprising reverse transcribing viral RNA to synthesize a complementary DNA sequence followed by amplifying the DNA using primers which are selective for the Bayou hantavirus and detecting the presence of amplification, thereby indicating presence of the Bayou hantavirus in the sample.

Bayou hantavirus and related methods

The present invention relates to the discovery and isolation of a novel hantavirus designated the Black Creek Canal hantavirus. In particular, the present invention relates to nucleic acids of the newly discovered virus and to nucleic acid reagents (primers and probes), purified polypeptides and antibodies for use in methods of detection and prevention of infection by the virus. A vaccine or purified immunogenic polypeptide of the Black Creek Canal hantavirus in a pharmaceutically acceptable carrier is provided. A vector comprising the nucleic acids of the invention is provided. A method of detecting the presence of a hantavirus in a subject comprising contacting an antibody-containing sample from the subject with a purified polypeptide of the invention and detecting the reaction of the polypeptide and the antibody is provided. A method of detecting the presence of the Black Creek Canal hantavirus is provided comprising reverse transcribing viral RNA to synthesize a complementary DNA sequence followed by amplifying the DNA using primers which are selective for the Black Creek Canal hantavirus and detecting the presence of amplification, thereby indicating presence of the Black Creek Canal hantavirus in the sample.

Black creek canal hantavirus and related methods

Growing community of inventors

Atlanta, GA, United States of America

Stuart T Nichol